RESUMO
This paper reports the simulation and optimization of heterojunction perovskite solar cells (PSCs) with a proposed structure of TiO2/i-CH3NH3SnBr3/CsPbI3/Al(BSF) using SCAPS-1D software. The purpose of this study is to investigate the performance of the PSC with CsPbI3 perovskite active layers and i-CH3NH3SnBr3 as the permeable layer. Therefore, the thicknesses of the layers of the heterojunction perovskite are modified in order to find a better conversion efficiency of the solar cell, where the latter's performance is improved by optimizing the absorber's thickness, which is found to be 1 µm, with a permeable layer of 15 µm. The device efficiency of the i-CH3NH3SnBr3/CsPbI3 heterojunction is improved to 38.98%, and optimized parameters are Voc = 1.21 mV, Jsc = 35.63 mA/cm2, and FF = 89.84%. The acceptor concentration (Na), donor concentration (Nd), defect density, and series and shunt resistances are also investigated.
RESUMO
Sodium-glucose cotransporter-2 inhibitor (SGLT2i) in patients with type 2 diabetes reduces the risk of serious heart failure events, specifically the risk of hospitalization for heart failure, and cardiovascular death. The benefit is most apparent in patients with a heart failure with reduced ejection fraction (HFrEF). Dapagliflozin and empagliflozin reduced the risk of cardiovascular death and hospitalizations for heart failure in patients with established HFrEF, including those without diabetes. Considering the magnitude of the problem and the expected benefit on the target population, an Egyptian consensus document was conducted to demonstrate the importance of and the critical knowledge needed for effective and safe implementation of SGLT2i in the daily practice for the management of patients with HFrEF.
